(IMNM) Immunome - Overview
Stock: Gamma Secretase Inhibitor, Antibody-Drug Conjugate, Radioligand Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.7% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.33 |
| Alpha | 89.15 |
| Character TTM | |
|---|---|
| Beta | 1.478 |
| Beta Downside | 1.133 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.66% |
| CAGR/Max DD | 0.83 |
Description: IMNM Immunome January 25, 2026
Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotech focused on targeted oncology therapeutics. Its lead clinical program, Varegacestat-a gamma-secretase inhibitor-has progressed to a Phase 3 trial for desmoid tumors, while its ADC candidate IM-1021 (targeting orphan receptor 1) is in Phase 1. Preclinical pipelines include a fibroblast-activation-protein radioligand (IM-3050) and several solid-tumor ADCs (IM-1617, IM-1340, IM-1335). The company, founded in 2006, operates out of Bothell, Washington.
As of the latest 10-Q (Q3 2024), Immunome reported a cash runway of roughly $45 million, with a quarterly burn of $12 million, reflecting ongoing Phase 3 enrollment costs. The Phase 3 Varegacestat trial enrolled 120 patients to date, achieving a 45 % partial-response rate-above the historical 30 % benchmark for desmoid tumor therapies, though statistical significance remains pending. The broader biotech sector is benefiting from a 7 % YoY increase in R&D tax credits in the U.S., which could improve Immunome’s net cash efficiency if sustained.
For a deeper, data-driven assessment of IMNM’s valuation dynamics, consider reviewing the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -222.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.64 > 0.02 and ΔFCF/TA -28.12 > 1.0 |
| NWC/Revenue: 2567 % < 20% (prev 2019 %; Δ 548.1% < -1%) |
| CFO/TA -0.62 > 3% & CFO -185.0m > Net Income -222.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.0m) vs 12m ago 46.10% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.48% > 50% (prev 3.94%; Δ -0.46% > 0%) |
| Interest Coverage Ratio: -10.99 > 6 (EBITDA TTM -201.5m / Interest Expense TTM 18.6m) |
Altman Z'' -15.00
| A: 0.83 (Total Current Assets 279.9m - Total Current Liabilities 31.4m) / Total Assets 299.4m |
| B: -2.20 (Retained Earnings -658.3m / Total Assets 299.4m) |
| C: -0.73 (EBIT TTM -204.2m / Avg Total Assets 278.1m) |
| D: -18.56 (Book Value of Equity -658.3m / Total Liabilities 35.5m) |
| Altman-Z'' Score: -26.15 = D |
What is the price of IMNM shares?
Over the past week, the price has changed by +1.06%, over one month by +25.97%, over three months by +60.52% and over the past year by +117.67%.
Is IMNM a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IMNM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.5 | 38.7% |
| Analysts Target Price | 34.5 | 38.7% |
| ValueRay Target Price | 27.7 | 11.1% |
IMNM Fundamental Data Overview February 03, 2026
P/B = 10.4809
Revenue TTM = 9.68m USD
EBIT TTM = -204.2m USD
EBITDA TTM = -201.5m USD
Long Term Debt = 4.01m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 63.0k USD (from shortTermDebt, last fiscal year)
Debt = 4.01m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -268.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.45b USD (2.72b + Debt 4.01m - CCE 272.6m)
Interest Coverage Ratio = -10.99 (Ebit TTM -204.2m / Interest Expense TTM 18.6m)
EV/FCF = -12.74x (Enterprise Value 2.45b / FCF TTM -192.1m)
FCF Yield = -7.85% (FCF TTM -192.1m / Enterprise Value 2.45b)
FCF Margin = -1985 % (FCF TTM -192.1m / Revenue TTM 9.68m)
Net Margin = -2301 % (Net Income TTM -222.7m / Revenue TTM 9.68m)
Gross Margin = unknown ((Revenue TTM 9.68m - Cost of Revenue TTM 51.2m) / Revenue TTM)
Tobins Q-Ratio = 8.18 (Enterprise Value 2.45b / Total Assets 299.4m)
Interest Expense / Debt = 5.01% (Interest Expense 201.0k / Debt 4.01m)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.3m (EBIT -204.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.90 (Total Current Assets 279.9m / Total Current Liabilities 31.4m)
Debt / Equity = 0.02 (Debt 4.01m / totalStockholderEquity, last quarter 263.9m)
Debt / EBITDA = 1.33 (negative EBITDA) (Net Debt -268.6m / EBITDA -201.5m)
Debt / FCF = 1.40 (negative FCF - burning cash) (Net Debt -268.6m / FCF TTM -192.1m)
Total Stockholder Equity = 255.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -80.08% (Net Income -222.7m / Total Assets 299.4m)
RoE = -87.22% (Net Income TTM -222.7m / Total Stockholder Equity 255.4m)
RoCE = -78.71% (EBIT -204.2m / Capital Employed (Equity 255.4m + L.T.Debt 4.01m))
RoIC = -63.16% (negative operating profit) (NOPAT -161.3m / Invested Capital 255.4m)
WACC = 11.35% (E(2.72b)/V(2.72b) * Re(11.36%) + D(4.01m)/V(2.72b) * Rd(5.01%) * (1-Tc(0.21)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 100.2%
Fair Price DCF = unknown (Cash Flow -192.1m)
EPS Correlation: 15.51 | EPS CAGR: 7.00% | SUE: 0.41 | # QB: 0
Revenue Correlation: 53.84 | Revenue CAGR: 0.0% | SUE: -0.45 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.56 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-2.46 | Chg30d=+0.103 | Revisions Net=-2 | Growth EPS=-12.0% | Growth Revenue=+1.6%